𝗖𝗼𝗺𝗶𝗻𝗴 𝗼𝘂𝘁 𝗼𝗳 𝗝𝗣𝗠 𝟮𝟬𝟮𝟲 | the market is clearly rewarding differentiated science and focused execution — exactly where we’ve built our science and foundation. Our conversations this week highlighted strong enthusiasm for programs that pair breakthrough biology with a de‑risked, multi‑shot‑on‑goal strategy, and our platform sits squarely in that category. As capital flows back into high‑quality oncology assets, 𝗪𝗲’𝗿𝗲 𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻𝗲𝗱 𝘁𝗼 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗼𝘂𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆, 𝗽𝘂𝗿𝘀𝘂𝗲 𝗮𝗻 𝗲𝘅𝗽𝗲𝗱𝗶𝘁𝗲𝗱 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗽𝗮𝘁𝗵, 𝗳𝗮𝘀𝘁-𝘁𝗿𝗮𝗰𝗸 𝗖𝗠𝗖 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁, 𝗮𝗻𝗱 𝗱𝗿𝗶𝘃𝗲 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗽𝗵𝗮𝘀𝗲 𝗼𝗳 𝗴𝗿𝗼𝘄𝘁𝗵 for patients, physicians, and investors alike.

𝗔𝗖𝗖𝗔𝗡𝗜𝗧𝗢 𝗜𝗡𝗖. / 𝗚𝗔𝗠-𝟬𝟱 𝗦𝗧𝗔𝗡𝗗𝗦 𝗢𝗨𝗧 𝗕𝗘𝗖𝗔𝗨𝗦𝗘 𝗢𝗙:

🧬 Novel MoA – targeting mitochondrial of cancer cells
🔬 Phase I clinical study ongoing in the U.S.
🎯 Interim Phase 1 data & strategic selection of indication
📈 Clear near-term value inflection based on clinical outcome and regulatory strategy

💡 𝗪𝗲’𝗿𝗲 𝗻𝗼𝘄 𝗲𝗻𝗴𝗮𝗴𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗮 𝘀𝗲𝗹𝗲𝗰𝘁 𝗴𝗿𝗼𝘂𝗽 𝗼𝗳 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 interested in early clinical-stage oncology opportunities with first-in-class mechanisms and defined growth pathways.

📩 𝗖𝗢𝗡𝗧𝗔𝗖𝗧 𝗨𝗦:
📧 uhayat@accanitotx.com
📞 +1-415-686-8822